# Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma

> **NCT00650923** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 61 (actual)

## Conditions studied

- Adult Anaplastic Astrocytoma
- Adult Anaplastic Oligodendroglioma
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Adult Mixed Glioma
- Recurrent Adult Brain Tumor

## Interventions

- **DRUG:** ziv-aflibercept
- **PROCEDURE:** radiation therapy
- **DRUG:** temozolomide
- **PROCEDURE:** pharmacological study
- **PROCEDURE:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00650923
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2013-06
- **Final completion:** 2013-12
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2014-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00650923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00650923, "Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00650923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*